Category Archives: BioUtah News
Nestmedic Selects Curavit Clinical Research as U.S. CRO Partner for Pioneering Prenatal Monitoring Trial
Nestmedic Selects Curavit Clinical Research as U.S. CRO Partner for Pioneering Prenatal Monitoring Trial
Microvascular Therapeutics Celebrates Major Achievements at ASE 2025 Scientific Sessions
Microvascular Therapeutics Celebrates Major Achievements at ASE 2025 Scientific Sessions
BioSeeker™ Powers Development of a First-of-Its-Kind Programmable Therapeutic for Respiratory Syncytial Virus (RSV)
BioSeeker™ Powers Development of a First-of-Its-Kind Programmable Therapeutic for Respiratory Syncytial Virus (RSV)
Canary Speech Achieves HITRUST e1 Certification for Voice Biomarker Platform
Canary Speech announces it has obtained HITRUST e1 Certification, reinforcing its commitment to cybersecurity related to its voice biomarker technology.
Recursion Acquires Full Rights to REV102, a Potential First-in-Class Oral ENPP1 Inhibitor for Hypophosphatasia
Recursion Acquires Full Rights to REV102, a Potential First-in-Class Oral ENPP1 Inhibitor for Hypophosphatasia
GE HealthCare’s Economic Impact Across Utah
GE HealthCare’s Economic Impact Across Utah
RefloDx Wins Trans Atlantic Angel Grand Prize
RefloDx Wins Trans Atlantic Angel Grand Prize.
bioMérieux strengthens its next-generation sequencing capabilities with the acquisition of Day Zero Diagnostics solutions and technologies
bioMérieux strengthens its next-generation sequencing capabilities with the acquisition of Day Zero Diagnostics solutions and technologies
DGENTHERA AND NUSANO SIGN LETTER OF INTENT FOR ASTATINE‑211 SUPPLY
ALPHA-EMITTING RADIOISOTOPE EXPECTED TO PLAY AN ESSENTIAL ROLE IN NEXT-GENERATION TARGETED CANCER THERAPIES
Halia Therapeutics Completes First-in-Human Phase 1 Study of HT-4253, a Novel LRRK2 Inhibitor Targeting Neuroinflammation
Completion of SAD/MAD trial marks advancement toward further clinical development of HT-4253 in Alzheimer’s and other neurodegenerative diseases.
Nelson Labs to Double Cleanroom Capacity to Support Growing Demand for Sterility Assurance Services
Strategic Expansion in Salt Lake City Headquarters Will Meet Stringent EU GMP Annex 1 Requirements
RATIO THERAPEUTICS AND NUSANO ENTER LONG-TERM, MULTI-ISOTOPE SUPPLY AGREEMENT TO BOOST PRODUCTION OF CANCER RADIOPHARMACEUTICALS
AGREEMENT PROVIDES RATIO ACCESS TO NUSANO-PRODUCED RADIOISOTOPES FOR ONCOLOGY DIAGNOSTICS AND THERAPEUTICS
